Clinical trial
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2…
NCT00146042 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00146042 |
|---|---|
| Title | UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer |
| Official title | Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER-2 Positive Metastatic Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Docetaxel, Trastuzumab, Erythromycin Breath Test (ERMBT) |
| Enrollment | 22 |
| Start date | Mar 1, 1999 |
| Primary completion | Mar 1, 2004 |
| Completion | Mar 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Oct 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: